Carly Robinson

Cooley advised Scorpion Therapeutics in its collaboration agreement with AstraZeneca to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.

Under the terms of the collaboration agreement, Scorpion will receive an upfront cash payment of $75 million and is eligible to receive additional success-based payments in the form of option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low-double digits. In the event Scorpion opts into co-developing and co-promoting a nominated program, Scorpion will participate in the operating costs and be entitled to a proportionate share of the economics in the US, subject to certain adjustments.

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its license, development and commercialization agreement with Bristol Myers Squibb for its TCR bispecific candidate, IMA401. Lawyers Ken Krisko, Carly Robinson, Brian Stalter and Stephanie Palmer led the Cooley team advising Immatics.

Cooley advised Prothena, a late-stage clinical company with a robust pipeline of novel investigational therapeutics, on its agreement to sell its clinical-stage antibody PRX004 and broader amyloid transthyretin (ATTR) amyloidosis program to Novo Nordisk for $1.2 billion. Partners Marya Postner and Barbara Borden led the Cooley team advising Prothena.

Cooley advised RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, on its definitive agreement to be acquired by Bristol Myers Squibb.

Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering.